VascVersa is new Regenerative Medicine company recently spun out from Queen's University in Belfast. Our Vision is to commercialise living medicines to reinvigorate patients lives. Utilising Angicyte technology we are developing new cell therapies for vascular regeneration.
Location: United Kingdom, Northern Ireland, Belfast
Employees: 1-10
Total raised: $7.01M
Founded date: 2008
Investors 1
| Date | Name | Website |
| 19.05.2022 | Clarendon ... | clarendon-... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.08.2022 | Series A | $6.41M | - |
| 07.08.2022 | Seed | $604.3K | - |
Mentions in press and media 7
| Date | Title | Description |
| 24.08.2022 | Cell Therapy Processing Market to Cross Valuation of $12,062 Million by 2026 | 27.8% CAGR | Cell Therapy Processing Market C Cell therapy processing market was valued at $1,695 Mn in 2018, and is projected to reach $12,062 Mn by 2026, registering a CAGR of 27.8% from 2019 to 2026. PORTLAND, OREGON, UNITED STATES, August 24, 2022 /... |
| 08.08.2022 | Cell therapy startup Eyestem raises ₹51 crore from BE, Alkem & Natco | ETtech(L to R) Dr Rajarshi Pal, Dr Jogin Desai & Dr Rajani Battu, founders, Eyestem Eyestem, a Bengaluru-based cell therapy company, on Monday, said it has raised Rs 51 crore in a Series A round led by three pharma majors — Biological E... |
| 08.08.2022 | Cell Therapy Firm Eyestem Raises $6.4 Million In Series A Round | Bengaluru-based cell therapy company Eyestem has raised $6.4 million (Rs 51 crore) in a Series A round of funding. The funding round was led by three pharma majors–Biological E Limited (BE), Alkem, NATCO, and Anurag and Karan Bagaria, promo... |
| 25.10.2021 | Juventas Cell Therapy closes a $63M funding round as it eyes a big push for blood cancer hopeful | Juventas has grabbed a $63 million series C to advance its CASI Pharmaceuticals-partnered drug CNCT19. The new swag will be used toward an NDA for the cell therapy as it eyes a future sales plan for the drug. CASI, which said it welcomed th... |
| 23.06.2021 | Abata hopes to find ‘perfect fit’ with MS cell therapy after $95M series A | After three and a half years of incubation at Third Rock Ventures, Abata Therapeutics is ready to unveil itself with $95 million in series A funds to bring cell therapies into the clinic for autoimmune and inflammatory diseases. First up, a... |
| - | Temasek-backed cell therapy firm nets $126m for cancer treatment research | InvestmentsNews Qishin Tariq · 18h ago · 1 min readTemasek-backed cell therapy firm nets $126m for cancer treatment research Singapore-based cell therapy company Tessa Therapeutics, which carries out research for cancer treatments, has rais... |
| - | Cell therapy company Eyestem raises ₹51 crore in funding | Eyestem, a Bengaluru-based cell therapy company, announced raising ₹51 crore in a Series A round led by three pharma companies- Biological E. Ltd (BE), Alkem, NATCO, and Anurag and Karan Bagaria, promoters of Kemwell Biopharma. Existing inv... |